Find clinical trials for Acute Myeloid Leukemia (AML) in Phoenix, AZ
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Phoenix, AZ, USA:
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Scottsdale, Arizona, United States and 164 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
Gilbert, Arizona, United States and 23 other locations
to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...
Phase 2
Gilbert, Arizona, United States and 56 other locations
[GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who...
Phase 3
Phoenix, Arizona, United States and 71 other locations
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...
Phase 3
Phoenix, Arizona, United States and 222 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Scottsdale, Arizona, United States and 43 other locations
three separate safety run-in cohorts in neuroblastoma, acute myeloid leukemia (AML), and acute lymphobla...
Phase 1, Phase 2
Phoenix, Arizona, United States and 19 other locations
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocyti...
Phase 1, Phase 2
Gilbert, Arizona, United States and 7 other locations
menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....
Phase 1, Phase 2
Phoenix, Arizona, United States and 51 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia...
Phase 1
Phoenix, Arizona, United States and 23 other locations
Clinical trials
Research sites
Resources
Legal